MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics.

MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Abstract Text:

MicroRNAs are evolutionarily conserved small non-coding RNAs known to inhibit the translation of proteins by binding to the target transcript in the 3' untranslated region. Functional polymorphisms in 3' UTRs of several genes have been reported to be associated with diseases by affecting gene expression. The mechanism by which these polymorphisms affect gene expression and induce variability in a cell is not well understood. It has been suggested that these polymorphisms may interfere with regulatory elements that bind to untranslated region of a gene. Recently, a novel class of functional polymorphisms termed miRSNPs/polymorphisms was reported. defined as a polymorphism present at or near a microRNA binding sites of functional genes that can affect gene expression by interfering with a miRNA function. The work elucidated the mechanism of a functional miRSNP 829C-->T present in 3' UTR of dihydrofolate reductase, an important drug target. The SNP interferes with the miR24 microRNA function and leads to DHFR over expression and methotrexate resistance. In this article we highlight the importance of these miRSNPs or miR-polymorphisms in gene regulation and the mechanism by which these miRSNPs can induce variability in the SNP expressing mutant cell by using drug resistance as an example.

MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Cell cycle (Georgetown, Tex.)

VOLUME: 7

Page Numbers: 853-8

Journal Abbreviation: Cell Cycle

ISSN: 1551-4005

DAY: 28

MONTH: 01

YEAR: 2008

MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101137841

MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics.

AFFILIATION: Department of Pharmacology and Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Jersey, USA.

Country: United States

AGENCY: United States NCI

GRANT: CA 0810

ACRONYM: CA

MEDLINETA: Cell Cycle

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics Related Publications

• A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance.
• Absorption of leucovorin (NSC-3590) from a "mouthwash".
• Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases.
• Chemotherapeutic approaches to advanced carcinoma of the larynx.
• Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumors.
• Evaluation of dose-intense Ifosfamide, with and without edatrexate, in adults with sarcoma.
• Failure of leucovorin "rescue" in methotrexate treatment of psoriasis.
• Head and neck cancer. 3. Toxicity of 24-hour infusions of methotrexate (NSC-740) and protection by leucovorin (NSC-3590) in patients with epidermoid carcinomas.
• Implantable pump for long-term chemotherapy administration via the hepatic artery: has it fulfilled its promise?
• In vitro reconstructed normal human epidermis expresses differentiation-related proteoglycans.
• Methotrexate (NSC-740) in squamous cell carcinoma of the head and neck. II. Intermittent intravenous therapy.
• MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics.
• Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment.
• Pharmacodynamics of Uniform versus Nonuniform Warfarin Dosages.
• Preclinical studies with triazinate (NSC-139105), an antifolate drug, in beagle dogs and rhesus monkeys.
• Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase cDNA.
• Recent developments in chemotherapy of malignancy.
• Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's disease.
• The journal of clinical oncology: the initial years.
• Treatment of advanced neoplastic disease with 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037).
• [Not Available.]